HR Execs on the Move

Arcellx

www.arcellx.com

 
Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx`s mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. Arcellx`s lead product candidate, CART-ddBCMA, is being developed for the treatment of relapsed or refractory multiple myeloma (r/r MM) in an ongoing Phase 1 study. CART-ddBCMA has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations by the U.S. Food and Drug ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.arcellx.com
  • 25 West Watkins Mill Road Suite A
    Gaithersburg, MD USA 20878
  • Phone: 240.327.0603

Executives

Name Title Contact Details
Rami Elghandour
Chairman and Chief Executive Officer Profile
Kate Aiken
Chief People Officer Profile

Similar Companies

Nutripro Biosystems

Nutripro Biosystems, Inc is a Worthington, MN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Cloudbreak

Cloudbreak Therapeutics is a clinical-stage biotechnology company focusing on ocular drug development. Our mission is to help people see life better through medicine.

Diazyme

Diazyme is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Synthekine

Synthekine is an engineered cytokine therapeutics company developing disease-optimized treatments.

Aduro Biotech

Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro`s technology platforms, which are designed to harness the body`s natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro`s LADD technology platform is based on proprietary attenuated strains of Listeria that have been engineered to express tumor-associated antigens to induce specific and targeted immune responses. Based on compelling clinical data in advanced cancers, this platform is being developed as a treatment for multiple indications, including pancreatic, ovarian, lung and prostate cancers, mesothelioma and glioblastoma. Aduro`s STING Pathway Activator platform is designed to activate the intracellular STING receptor, resulting in a potent tumor-specific immune response. Aduro`s B-select monoclonal antibody platform includes a number of immune modulating assets in research and preclinical development. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms.